Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02814929Completed

Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey

Role: collaborator

NCT03789123Phase 4Unknown

Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma

Role: collaborator

NCT02708628Not ApplicableCompleted

The Efficacy of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development

Role: lead

NCT02393235Completed

A Comparative Analysis of Arterial Blood Flow in Unexplained Infertility, Tubal Infertility and Fertile Groups

Role: lead

All 4 trials loaded